Prevencio has been issued a patent from the United States Patent and Trademark Office for its blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery disease. The company utilised its artificial intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CADhs.
“Prevencio is pleased with the advancement of our patent portfolio, which is crucial for maintaining our competitive advantage,” said Rhonda Rhyne, president and chief executive officer of Prevencio. “This is the fourth patent issued for our novel AI-driven, multiple protein blood tests. We have several more patents pending.”
In research conducted with Massachusetts General Hospital (Boston, USA), HART CADhs demonstrated an 86% area under the curve (AUC) accuracy, outperforming standard-of-care tests such as exercise, echocardiography and nuclear stress tests which collectively had an accuracy of 52% AUC.
Rhyne added: “Given the cost, complexity, and pervasiveness of cardiovascular disease, our highly accurate and accessible HART blood tests are well-positioned to improve patient outcomes while reducing costs.”
In addition to the HART CADhs test for diagnosing heart artery obstruction, Prevencio offers a second multi-protein blood test, HART CVE, which assesses one-year risk of a heart attack, stroke or cardiovascular death. HART CADhs and HART CVE tests are currently available to medical professionals for patient use.
